By
It should come as no surprise that in large numbers, it seems almost everyone is contracting COVID-19, the Omicron variant. The US CDC anticipates this new strain to account for 93% or more of the current cases. Fortunately, infection with this strain produces a considerably less severe illness than the prior variants, particularly the Delta strain.Â
Those naturally immune and vaccinated can expect a mild and brief illness characterized by nasal congestion, runny nose, fever, and viral malaise. The unvaccinated and COVID-19 naĂŻve may have slightly more pronounced symptoms. Low rates of hospitalization and death are expected, particularly with early treatment. Most patients now get through the illness with simple over-the-counter measures and without the need for prescription medications or monoclonal antibodies.Â
By now, everyone should know the most effective initial treatment to handle the rapidly replicating Omicron virus in the nasal cavity is nasal and oral rinses with viricidal solutions. For severe cases in seniors or those with many background medications, the monoclonal antibody to seek is sotrivimab from GSK. This product was designed to be more effective against mutant strains.
Daily News PDF Archives – Jellyfish.NewsÂ